Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592596 | 0.89 | ABCG2 (0.56) | ADORA2AADORA1ABCG2CHRNA7MAPT | |
| SCHEMBL1592702 | 0.88 | ABCG2 (0.57) | ADORA2AADORA1ABCG2ABCB1CHRNA7 | |
| SCHEMBL28929978 | 0.85 | CHRNA7 (0.78) | CHRNA7MAPTSMN1; SMN2TUBB4ATUBB | |
| SCHEMBL1592591 | 0.83 | ABCG2 (0.63) | ADORA2AABCG2ABCB1MAPTSMN1; SMN2 | |
| SCHEMBL15131283 | 0.82 | KCNH3 (0.70) | ADORA2AADORA1ABCG2ABCB1MAPT | |
| SCHEMBL19227754 | 0.82 | MEN1 (0.72) | ADORA2AADORA1ABCG2CHRNA7MAPT | |
| SCHEMBL15094660 | 0.82 | MEN1 (0.72) | ADORA2AADORA1ABCG2CHRNA7MAPT | |
| SCHEMBL1592678 | 0.82 | CLK4 (0.61) | ADORA2AADORA1ABCG2ABCB1MAPT | |
| SCHEMBL29609042 | 0.81 | NFKB1 (0.64) | MAPTSMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL13326017 | 0.81 | NFKB1 (0.64) | MAPTSMN1; SMN2MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092490-A1 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2011-04-21 | — | — | US | disclosed |
| WO-2009118567-A2 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092490-A1 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | HRH2, HRH3, HRH4 | ADORA2A 173/4885ADORA1 233/4885ABCG2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.